leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 13:10:46 - browse：4

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Researchers on aging grapple with how to calculate biological age

WSS

Apple Watch's A

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Steward Health Care files for bankruptcy

HHS leader on health, climate change and biopharma emissions

Medicare says breakthrough device reimbursement rule to come by summer

Study: AI not yet building 'n

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

How to save PrEP access — and even expand it

FDA warns J&J's Abiomed: We will regulate your software

Continuity nursing helped my family in our darkest PICU moments

UnitedHealth’s board chair also owns a personal investment firm

Continuity nursing helped my family in our darkest PICU moments

After gene therapy, two congenitally deaf children hear for the first time

Guidelines to prevent youth baseball injuries need more muscle

What nurses really want: sufficient staffing for patient care

Supreme Court strikes down use of affirmative action

STAT Readout Newsletter: Today's biggest biotech updates

explore

Lawmakers consider Medicare pay reforms for doctors

Readout LOUD podcast: What to know about H5N1 bird flu

Elevance, private equity launch primary care company

Bird flu outbreak in cows is latest avian flu curveball

The EU Joint Clinical Assessment needs to live up to its promise

Hospital price transparency does save money, advocate argues

hotspot

hotspot

focus

Wikipedia